Chen et al. [97] also conferred that OM effectively targets BCR–ABL+ LICs in animal models of Ph+ CML also and deliberates a substantial survival benefit for leukemic mice. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.